Drug Trial Radar · NCT05398445
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
769
Actual
Start
May 31, 2022
Primary completion
Nov 28, 2024
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Conditions
- Atopic Dermatitis
Interventions
RocatinlimabDrug
Participants will receive Rocatinlimab subcutaneously.
PlaceboDrug
Participants will receive a placebo subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Time frame: Baseline and Week 24
- Number of Participants Who Achieved ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24Time frame: Baseline and Week 24
Locations
202 sites in 21 countries. Site status is shown where the registry gives one.
Cahaba Dermatology and Skin Health Center
Birmingham, Alabama
Alliance Dermatology and Mohs Center
Phoenix, Arizona
Anaheim Clinical Trials
Anaheim, California
First OC Dermatology
Fountain Valley, California
Kaiser Permanente - Glendale Medical Center
Glendale, California
Long Beach Research Institute
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Dermatology Research Associates
Los Angeles, California
Cura Clinical Research
Sherman Oaks, California
IMMUNOe Research Centers
Centennial, Colorado
Skin Care Research Incorporated
Boca Raton, Florida
Palm Beach Dermatology Group
Delray Beach, Florida
Global Research Associates
Homestead, Florida
Healthy Life Research
Miami, Florida
Savin Medical Group LLC
Miami Lakes, Florida
Kirsch Dermatology LLC
Naples, Florida
Pure Skin Dermatology and Aesthetics
Orlando, Florida
Industrial Medicine Associates Ima Clinical Research Inc
St. Petersburg, Florida
Genesis Clinical Research LLC
Tampa, Florida
Treasure Valley Medical Research
Boise, Idaho
DeNova Research
Chicago, Illinois
Dundee Dermatology
West Dundee, Illinois
The Indiana Clinical Trials Center PC
Plainfield, Indiana
Institute for Asthma and Allergy
Chevy Chase, Maryland
Continental Clinical Solutions, LLC
Towson, Maryland
Henry Ford Health System
Detroit, Michigan
Onyx Clinical Research
Flint, Michigan
Dermatology and Skin Cancer Center of Lees Summit
Lee's Summit, Missouri
Jubilee Clinical Research Inc
Las Vegas, Nevada
Allcutis Research, Llc - Portsmouth
Portsmouth, New Hampshire
Continental Clinical Solutions - Cherry Hill
Cherry Hill, New Jersey
Industrial Medicine Associates Ima Clinical Research Inc
Hartsdale, New York
Sadick Research Group
New York, New York
Dermatology Specialists of Charlotte
Charlotte, North Carolina
Onsite Clinical Solutions
Charlotte, North Carolina
Wilmington Dermatology Center
Wilmington, North Carolina
The Skin Surgery Center for Clinical Research
Winston-Salem, North Carolina
Optima Research
Boardman, Ohio
ClinOhio Research Services
Columbus, Ohio
Unity Clinical Research
Oklahoma City, Oklahoma
Showing 40 of 202 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.